Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT06535399
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Local Institution - 0004, Chandler, Arizona, United States
🇺🇸Local Institution - 0005, Orlando, Florida, United States
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT06433505
- Locations
- 🇺🇸
Covance Clinical Research Unit - Madison, Madison, Wisconsin, United States
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT06425302
- Locations
- 🇺🇸
Local Institution - 0020, New Brunswick, New Jersey, United States
🇩🇪Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany
🇮🇹Local Institution - 0179, Rozzano, Milano, Italy
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 82
- Registration Number
- NCT06417229
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT06411730
- Locations
- 🇺🇸
Local Institution - 0001, Anaheim, California, United States
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 194
- Registration Number
- NCT06408259
- Locations
- 🇷🇴
Local Institution - 0088, Bucharest, București, Romania
🇺🇸Local Institution - 0130, Sacramento, California, United States
🇺🇸UCSF Benioff Children's Hospital San Francisco, San Francisco, California, United States
A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 36
- Registration Number
- NCT06363630
- Locations
- 🇺🇸
Local Institution - 0002, Atlanta, Georgia, United States
🇺🇸Local Institution - 0001, Lenexa, Kansas, United States
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 850
- Registration Number
- NCT06356129
- Locations
- 🇺🇸
Cancer Care Specialists, Reno, Nevada, United States
🇺🇸Local Institution - 0498, East Brunswick, New Jersey, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT06318676
- Locations
- 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸PANAX, Miami Lakes, Florida, United States
🇺🇸Omega Research Group - Orlando, Orlando, Florida, United States
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Celgene
- Registration Number
- NCT06232707
- Locations
- 🇺🇸
Local Institution - 0088, Los Angeles, California, United States
🇺🇸Local Institution - 0324, Baltimore, Maryland, United States
🇦🇺Local Institution - 0022, Waratah, New South Wales, Australia